Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had ...

Scientists have found a way to 'intercept' pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able to ...

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS ...

Results showed that FGFR2 gene deletion led to significantly fewer precancerous lesions and delayed PDAC tumor formation ...

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD ... frequently associated with mutations in EGFR, KRAS, ALK, and BRAF, while LUSC is ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.